Enjamb Labs
Full stack AI Agents accelerating Biopharma R&D
What they do
Biopharma drug development is slow and resource-intensive due to fragmented evidence synthesis, regulatory authoring, and clinical statistical programming workflows.
Enjamb Labs provides a full-stack, auditable AI agent workspace that synthesizes clinical evidence, drafts and audits regulatory documents, and automates clinical stats programming (SDTM/ADaM/TFL/QC) across the drug program.
Biopharma R&D, clinical development, regulatory, and biostatistics teams running drug programs from preclinical through approval.
Founders
Rayan is an ML and biology researcher. At 17, he published a first-author cancer ML paper in JMIR that beat SOTA models by 20%. He researched drug-therapeutics for pesticide poisoning(30% more effective) and presented at top bio conferences (SOT, ISCB).
Maadhav is an AI researcher. He was the youngest engineer at Dell's AI Lab, shipping AI CPU optimization on supercomputing infra,. He also worked at Broadcom R&D developing SOTA AI ASICs. For fun, he built a Rocket League AI trained on 1M+ sessions that beats the top 1% of players.
Company timeline
- Founded2025
- YC batchSpring 2026
- StatusActive
- Team size2 people
- LocationSan Francisco, CA, USA
Similar startups
